These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6913237)

  • 1. [Drug information: antiparkinson agents. II. Dopaminergic agents].
    Veje JO
    Sygeplejersken; 1981 Sep; 81(36):9, 26. PubMed ID: 6913237
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug information: antiparkinson agents. I. Anticholinergic agents].
    Veje VO
    Sygeplejersken; 1981 Sep; 81(34):11. PubMed ID: 6913222
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug information: antiparkinson agents III. Amantadine (Symmetrel), bromocriptine (Parlodel)].
    Veje JO
    Sygeplejersken; 1981 Sep; 81(38):20. PubMed ID: 6914040
    [No Abstract]   [Full Text] [Related]  

  • 4. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
    Millan MJ; Maiofiss L; Cussac D; Audinot V; Boutin JA; Newman-Tancredi A
    J Pharmacol Exp Ther; 2002 Nov; 303(2):791-804. PubMed ID: 12388666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impulse control disorders and dopaminergic drugs.
    Morgan JC; Iyer SS; Sethi KD
    Arch Neurol; 2006 Feb; 63(2):298-9; author reply 299. PubMed ID: 16476826
    [No Abstract]   [Full Text] [Related]  

  • 8. [The effectiveness of the use of new types of antiparkinson agents].
    Federmann J; Honzáková L; Roth B; Stika L
    Cesk Zdrav; 1981 Jun; 29(6):229-41. PubMed ID: 7261170
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic effectiveness of modern antiparkinson agents].
    Kurako IuL; Volianskiĭ VE; Fadeev SM
    Vrach Delo; 1981 Feb; (2):7-11. PubMed ID: 7222616
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease.
    Shin HW; Kang SY; Sohn YH
    Mov Disord; 2005 Dec; 20(12):1640-3. PubMed ID: 16092109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of anticholinergic antiparkinson agents against adverse drug reactions in a psychiatric department. A quality assurance project].
    Mikkelsen VR
    Ugeskr Laeger; 1998 Jul; 160(29):4323-5. PubMed ID: 9679438
    [No Abstract]   [Full Text] [Related]  

  • 12. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
    Baron MS; Dalton WB
    Mov Disord; 2003 Oct; 18(10):1208-9. PubMed ID: 14534933
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of dopaminergic anti-Parkinsonian agents on inflammatory reactions in rats.
    Hirschelmann R; Thong NT
    Pharmazie; 2000 Jun; 55(6):469. PubMed ID: 10907263
    [No Abstract]   [Full Text] [Related]  

  • 14. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.
    Goetz CG
    Exp Neurol; 1997 Mar; 144(1):17-20. PubMed ID: 9126145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?].
    Defer GL
    Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847
    [No Abstract]   [Full Text] [Related]  

  • 16. Gas chromatography/mass spectrometric identification of dopaminergic metabolites in striata of rats treated with L-DOPA.
    Loutelier-Bourhis C; Legros H; Bonnet JJ; Costentin J; Lange CM
    Rapid Commun Mass Spectrom; 2004; 18(5):571-6. PubMed ID: 14978802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New types of dopaminergic treatment. The Danish Society of Movement Disorders].
    Karlsborg M; Regeur L
    Ugeskr Laeger; 2006 Mar; 168(12):1209. PubMed ID: 16571300
    [No Abstract]   [Full Text] [Related]  

  • 18. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
    Ceballos-Baumann AO
    MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.